Back to first-pass browser

First-pass extracted concept

androgen signaling inhibition

Candidate: concept label1 source documents3 linked claims
Jump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

ASI

Evidence Snippets

Increased ErbB2 signaling is a rapid adaptation to ASI and contributes to castration resistance.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1expression changesupports2025Source 1DOIPubMed

d16ERBB2 is increased after androgen signaling inhibition and contributes to increased ErbB2 signaling.

Quoted textsource-backed
Overexpression of an active ERBB2 splice variant (d16ERBB2) was also increased rapidly after ASI in prostate cancer cells and was found in a subset of CRPC. Increases in NRG1 and d16ERBB2 contribute to increased ErbB2 signaling.
Claim 2expression changesupports2025Source 1DOIPubMed

NRG1 is increased after androgen signaling inhibition and contributes to increased ErbB2 signaling.

Quoted textsource-backed
The ErbB3/ErbB2-activating ligand NRG1 was found by IHC in ∼75% of neoadjuvant-treated tumors. NRG1 mRNA was rapidly increased by ASI in prostate cancer cells and xenografts and was increased in post-ASI data sets. Increases in NRG1 and d16ERBB2 contribute to increased ErbB2 signaling.
Claim 3mechanistic rolesupports2025Source 1DOIPubMed

Increased ErbB2 signaling is a rapid adaptation to androgen signaling inhibition and contributes to castration resistance in prostate cancer.

Quoted textsource-backed
Increased ErbB2 signaling is a rapid adaptation to ASI and contributes to castration resistance.